New and Emerging Strategies for Targeting Genomic Instability and Overcoming Drug Resistance in Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 25 October 2024 | Viewed by 120
Special Issue Editor
Special Issue Information
Dear Colleagues,
Advances in targeted therapies and immunotherapies have greatly expanded the treatment landscape for lung cancer, defining opportunities for precision medicine and improving the quality of life and survival rates for patients. Although significant progress has been made, lung cancer recurrence driven by drug resistance to all treatment modalities remains a major clinical barrier to further improving patient outcomes. Genomic instability is a well-established hallmark of lung and other cancers that promotes tumor evolution and the development of drug resistance. However, too much instability can be lethal to cancer cells due to excessive aneuploidy and cellular stress. Thus, genomic instability in cancer is a fine balance between its tumor-promoting advantages and potentially lethal consequences. Given its specificity to malignant cells, potentiating genomic instability to lethal levels could be an effective treatment strategy for combating tumor progression and drug resistance in lung cancer patients. This Special Issue focuses on new developments in targeting genomic instability and therapeutic approaches for overcoming drug resistance in lung cancer.
Dr. Kelsie L. Thu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- genomic instability
- drug resistance
- treatment strategy
- targeted therapy
